Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alessandra Lugaresi is active.

Publication


Featured researches published by Alessandra Lugaresi.


Multiple Sclerosis Journal | 2006

Autologous stem cell transplantation for progressive multiple sclerosis : Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database

Riccardo Saccardi; Tomas Kozak; C Bocelli-Tyndall; A Fassas; A. Kazis; Eva Havrdova; Enric Carreras; Albert Saiz; Bob Löwenberg; P Aw te Boekhorst; F. Gualandi; Harry Openshaw; G Longo; Francesca Pagliai; Luca Massacesi; E Deconink; Jian Ouyang; F Jz Nagore; Juan Besalduch; I A Lisukov; A Bonini; Elisa Merelli; Shimon Slavin; Alois Gratwohl; J Passweg; Alan Tyndall; Andreas J. Steck; M Andolina; M Capobianco; J Ld Martin

Over the last decade, hematopoietic stem cells transplantation (HSCT) has been increasingly used in the treatment of severe progressive autoimmune diseases. We report a retrospective survey of 183 multiple sclerosis (MS) patients, recorded in the database of the European Blood and Marrow Transplantation Group (EBMT). Transplant data were available from 178 patients who received an autologous graft. Overall, transplant related mortality (TRM) was 5.3% and was restricted to the period 1995-2000, with no further TRM reported since then. Busulphan-based regimens were significantly associated with TRM. Clinical status at the time of transplant and transplant techniques showed some correlations with toxicity. No toxic deaths were reported among the 53 patients treated with the BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan)/antithymocyte globulin (ATG) regimen without graft manipulation, irrespective of their clinical condition at the time of the transplant. Improvement or stabilization of neurological conditions occurred in 63% of patients at a median follow-up of 41.7 months, and was not associated with the intensity of the conditioning regimen. In this large series, HSCT was shown as a promising procedure to slow down progression in a subset of patients affected by severe, progressive MS; the safety and feasibility of the procedure can be significantly improved by appropriate patient selection and choice of transplant regimen.


Neurology | 2014

Fingolimod after natalizumab and the risk of short-term relapse

Vilija Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne J. Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; D. Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven

Objective: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse on fingolimod. Methods: Data were obtained from the MSBase Registry. Relapse rates (RRs) for each patient group were compared using adjusted negative binomial regression. Survival analyses coupled with adjusted Cox regression were used to model predictors of time to first relapse on fingolimod. Results: A total of 536 patients (natalizumab-fingolimod [n = 89]; IFN-β/GA-fingolimod [n = 350]; naive-fingolimod [n = 97]) were followed up for a median 10 months. In the natalizumab-fingolimod group, there was a small increase in RR on fingolimod (annualized RR [ARR] 0.38) relative to natalizumab (ARR 0.26; p = 0.002). RRs were generally low across all patient groups in the first 9 months on fingolimod (RR 0.001–0.13). However, 30% of patients with disease activity on natalizumab relapsed within the first 6 months on fingolimod. Independent predictors of time to first relapse on fingolimod were the number of relapses in the prior 6 months (hazard ratio [HR] 1.59 per relapse; p = 0.002) and a gap in treatment of 2–4 months compared to no gap (HR 2.10; p = 0.041). Conclusions: RRs after switch to fingolimod were low in all patient groups. The strongest predictor of relapse on fingolimod was prior relapse activity. Based on our data, we recommend a maximum 2-month treatment gap for switches to fingolimod to decrease the hazard of relapse. Classification of evidence: This study provides Class IV evidence that RRs are not higher in patients with multiple sclerosis switching to fingolimod from natalizumab compared to those patients switching to fingolimod from other therapies.


PLOS ONE | 2013

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

Tomas Kalincik; Tim Spelman; Maria Trojano; Pierre Duquette; Guillermo Izquierdo; Pierre Grammond; Alessandra Lugaresi; Raymond Hupperts; Edgardo Cristiano; Vincent Van Pesch; Francois Grand'Maison; D. Spitaleri; Maria Edite Rio; S. Flechter; Celia Oreja-Guevara; Giorgio Giuliani; Aldo Savino; Maria Pia Amato; Thor Petersen; Ricardo Fernandez-Bolanos; Roberto Bergamaschi; Gerardo Iuliano; Cavit Boz; Jeannette Lechner-Scott; Norma Deri; Orla Gray; Freek Verheul; Marcela Fiol; Michael Barnett; Erik van Munster

Objectives To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Methods Treatment discontinuations were evaluated in all patients within the MSBase registry who commenced interferon β-1a SC thrice weekly (n = 4678). Furthermore, we assessed 2-year clinical outcomes in 1220 patients treated with interferon β-1a in either dosage (22 µg or 44 µg) as their first disease modifying agent, matched on propensity score calculated from pre-treatment demographic and clinical variables. A subgroup analysis was performed on 456 matched patients who also had baseline MRI variables recorded. Results Overall, 4054 treatment discontinuations were recorded in 3059 patients. The patients receiving the lower interferon dosage were more likely to discontinue treatment than those with the higher dosage (25% vs. 20% annual probability of discontinuation, respectively). This was seen in discontinuations with reasons recorded as “lack of efficacy” (3.3% vs. 1.7%), “scheduled stop” (2.2% vs. 1.3%) or without the reason recorded (16.7% vs. 13.3% annual discontinuation rate, 22 µg vs. 44 µg dosage, respectively). Propensity score was determined by treating centre and disability (score without MRI parameters) or centre, sex and number of contrast-enhancing lesions (score including MRI parameters). No differences in clinical outcomes at two years (relapse rate, time relapse-free and disability) were observed between the matched patients treated with either of the interferon dosages. Conclusions Treatment discontinuations were more common in interferon β-1a 22 µg SC thrice weekly. However, 2-year clinical outcomes did not differ between patients receiving the different dosages, thus replicating in a registry dataset derived from “real-world” database the results of the pivotal randomised trial. Propensity score matching effectively minimised baseline covariate imbalance between two directly compared sub-populations from a large observational registry.


Neurology | 2010

Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis

Maria Pia Amato; Emilio Portaccio; A. Ghezzi; Bahia Hakiki; Valentina Zipoli; Vittorio Martinelli; Lucia Moiola; Francesco Patti; L. La Mantia; Giovanni Luigi Mancardi; Claudio Solaro; M. R. Tola; Carlo Pozzilli; L. De Giglio; Rocco Totaro; Alessandra Lugaresi; V. Di Tommaso; Damiano Paolicelli; M. G. Marrosu; Giancarlo Comi; Fabio Pellegrini; Maria Trojano

Objective: To assess pregnancy and fetal outcomes after in utero exposure to interferon-β (IFNβ) in all pregnancies occurring in women with multiple sclerosis (MS) during the study period, with a specific focus on the risk of spontaneous abortion. Methods: In this cohort study, data were gathered through a standardized, semi-structured interview. Patients who discontinued IFNβ less than 4 weeks from conception (exposed) were compared with those who had discontinued the drug at least 4 weeks from conception or who were never treated (not exposed). Possible confounders were handled through multivariate analyses adjusted for propensity score (PS). Results: We collected data on 396 pregnancies in 388 women, 88 classified as exposed (mean exposure 4.6 ± 5.8 weeks). IFNβ exposure was not associated with an increased risk of spontaneous abortion (PS-adjusted odds ratio [OR] 1.08, 95% confidence interval [CI] 0.4 to 2.9, p = 0.88), although it was associated with both lower baby weight (PS-adjusted β −113.8, p < 0.0001) and length (PS-adjusted β −1.102, p < 0.0001). Proportion of spontaneous abortion in exposed patients fell within the range expected for the Italian population in the same period. IFNβ exposure (PS-adjusted OR 2.11, 95% CI 1.18 to 3.78, p = 0.012) and cesarean delivery were the only predictors of preterm delivery. In the exposed group, we did not observe any significant fetal complications, malformations, or developmental abnormalities over a median follow-up of 2.1 years. Conclusions: Our findings point to the relative safety of IFNβ exposure times of up to 4 weeks and can assist neurologists facing therapeutic decisions in women with MS with a pregnancy plan.


Journal of Neurology | 2004

Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis

Giovanni Savettieri; Demetrio Messina; Virginia Andreoli; Simona Bonavita; Carlo Caltagirone; Rita Cittadella; Deborah Farina; Maria Fazio; Paolo Girlanda; Francesco Le Pira; Maria Liguori; Alessandra Lugaresi; Ugo Nocentini; A. Reggio; Giuseppe Salemi; Gioacchino Tedeschi; Maria Trojano; Paola Valentino; Aldo Quattrone

Abstract.Background:Cognitive impairment may occur at any time during the course of multiple sclerosis (MS), and it is often a major cause of disability in patients with the disease. The APOE-ε4 allele is the major known genetic risk factor for late onset familial and sporadic Alzheimer’s Disease (AD), and it seems to be implicated in cognitive decline in normal elderly persons.Objective:To investigate the clinical and genetic variables that can be associated with the cognitive decline in patients with MS.Methods:Five-hundred and three patients with clinically definite MS underwent a battery of neuropsychological tests and, according to the number of failed tests, were divided into cognitively normal and impaired. All patients were genotyped for APOE gene polymorphisms.Results:Fifty-six percent of MS patients showed, to different extents, cognitive impairment. Cognitive decline was predominant in men and was associated with disease duration, Kurtzke Expanded Disability Status Scale (EDSS) score, a low level of education, and, interestingly, the ε4 allele of the APOE gene. By contrast, cognitive impairment in women was independent of any investigated variable.Conclusion:The findings demonstrate that clinical and genetic factors play a role in men affected by MS developing cognitive impairment.


Multiple Sclerosis Journal | 2006

Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis

Ugo Nocentini; P Pasqualetti; Simona Bonavita; M Buccafusca; M. F. De Caro; Deborah Farina; Paolo Girlanda; F. Le Pira; Alessandra Lugaresi; A. Quattrone; A. Reggio; Giuseppe Salemi; Giovanni Savettieri; Gioacchino Tedeschi; Maria Trojano; Paola Valentino; Carlo Caltagirone

Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However, in the literature there are inconsistent reports on the prevalence of cognitive dysfunction, and separate data for the relapsing-remitting (RR) type of the disease are not always presented. In this study, we submitted 461 RRMS patients to a battery of neuropsychological tests to investigate their impairment in various cognitive domains. As a consequence of the exclusion criteria, the sample is not fully representative of the entire population of RRMS patients. In this selected sample, when only the eight scores of a core battery (Mental Deterioration Battery) were considered (with respective cutoffs), it emerged that 31% of the patients were affected by some degree of cognitive deficit. In particular, 15% had mild, 11.2% moderate and 4.8% had severe impairment. Information processing speed was the most frequently impaired area, followed by memory. When two other tests (SDMT and MCST) were added and cognitive domains were considered, it emerged that 39.3% of the patients were impaired in two or more domains. When four subgroups were obtained by means of cluster analysis and then compared, it emerged that information processing speed and memory deficits differentiated the still cognitively unimpaired from the mildly impaired MS patients. Significant associations were found between cognitive and clinical characteristics. However, due to the large sample size, clinically irrelevant relationships may also have emerged. Even with the limitations imposed by the sample selection and the possible underestimation of the prevalence and severity of cognitive dysfunction, these results seem to provide further evidence that information processing speed deficit may be an early and important marker of cognitive impairment in MS patients.


Annals of Neurology | 2015

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Tomas Kalincik; Dana Horakova; Tim Spelman; Vilija Jokubaitis; Maria Trojano; Alessandra Lugaresi; Guillermo Izquierdo; Csilla Rozsa; Pierre Grammond; Raed Alroughani; Pierre Duquette; Marc Girard; Eugenio Pucci; Jeannette Lechner-Scott; Mark Slee; Ricardo Fernandez-Bolanos; Francios Grand'Maison; Raymond Hupperts; Freek Verheul; Suzanne J. Hodgkinson; Celia Oreja-Guevara; D. Spitaleri; Michael Barnett; Murat Terzi; Roberto Bergamaschi; Pamela A. McCombe; J. L. Sanchez-Menoyo; Magdolna Simó; Tünde Csépány; Garbor Rum

In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents.


Annals of Neurology | 2009

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

Maria Trojano; Fabio Pellegrini; Damiano Paolicelli; Aurora Fuiani; Giovanni Bosco Zimatore; Carla Tortorella; Isabella Laura Simone; Francesco Patti; A. Ghezzi; Valentina Zipoli; Pasquin Rossi; Carlo Pozzilli; Giuseppe Salemi; Alessandra Lugaresi; Roberto Bergamaschi; Enrico Millefiorini; Marinella Clerico; G. Lus; M. Vianello; Carlo Avolio; Paola Cavalla; Vito Lepore; Paolo Livrea; Giancarlo Comi; Maria Pia Amato

Recent findings support greater efficacy of early vs. delayed interferon beta (IFNβ) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNβ treatment in definite relapsing‐remitting MS (RRMS) and to assess the optimal time to initiate IFNβ treatment with regard to the greatest benefits on disability progression.


Neurology | 2015

Autologous hematopoietic stem cell transplantation in multiple sclerosis A phase II trial

Giovanni Luigi Mancardi; Maria Pia Sormani; F. Gualandi; Albert Saiz; Enric Carreras; Elisa Merelli; Amedea Donelli; Alessandra Lugaresi; P. Di Bartolomeo; M.R. Rottoli; Alessandro Rambaldi; Maria Pia Amato; Luca Massacesi; M. Di Gioia; L. Vuolo; D. Currò; Luca Roccatagliata; Massimo Filippi; U. Aguglia; Pasquale Iacopino; Dominique Farge; Riccardo Saccardi

Objective: To assess in multiple sclerosis (MS) the effect of intense immunosuppression followed by autologous hematopoietic stem cells transplantation (AHSCT) vs mitoxantrone (MTX) on disease activity measured by MRI. Methods: We conducted a multicenter, phase II, randomized trial including patients with secondary progressive or relapsing-remitting MS, with a documented increase in the last year on the Expanded Disability Status Scale, in spite of conventional therapy, and presence of one or more gadolinium-enhancing (Gd+) areas. Patients were randomized to receive intense immunosuppression (mobilization with cyclophosphamide and filgrastim, conditioning with carmustine, cytosine-arabinoside, etoposide, melphalan, and anti-thymocyte globulin) followed by AHSCT or MTX 20 mg every month for 6 months. The primary endpoint was the cumulative number of new T2 lesions in the 4 years following randomization. Secondary endpoints were the cumulative number of Gd+ lesions, relapse rate, and disability progression. Safety and tolerability were also assessed. Twenty-one patients were randomized and 17 had postbaseline evaluable MRI scans. Results: AHSCT reduced by 79% the number of new T2 lesions as compared to MTX (rate ratio 0.21, p = 0.00016). It also reduced Gd+ lesions as well as the annualized relapse rate. No difference was found in the progression of disability. Conclusion: Intense immunosuppression followed by AHSCT is significantly superior to MTX in reducing MRI activity in severe cases of MS. These results strongly support further phase III studies with primary clinical endpoints. The study was registered as EUDRACT No. 2007-000064-24.


Annals of Neurology | 2004

The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy

Maria Lucia Valentino; Piero Barboni; Anna Ghelli; Laura Bucchi; Chiara Rengo; Alessandro Achilli; Antonio Torroni; Alessandra Lugaresi; Raffaele Lodi; Bruno Barbiroli; M.T. Dotti; Antonio Federico; Agostino Baruzzi; Valerio Carelli

A novel mitochondrial DNA (mtDNA) transition (3733G→A) inducing the E143 K amino acid change at a very conserved site of the NADH dehydrogenase subunit 1 (ND1) was identified in a family with six maternally related individuals with Lebers hereditary optic neuropathy (LHON) and in an unrelated sporadic case, all negative for known mutations and presenting with the canonical phenotype. The transition was not detected in 1,082 control mtDNAs and was heteroplasmic in several individuals from both pedigrees. In addition, the mtDNAs of the two families were found to belong to different haplogroups (H and X), thus confirming that the 3733G→A mutation occurred twice independently. Phosphorus magnetic resonance spectroscopy disclosed an in vivo brain and skeletal muscle energy metabolism deficit in the four examined patients. Muscle biopsy from two patients showed slight mitochondrial proliferation with abnormal mitochondria. Biochemical investigations in platelets showed partially insensitive complex I to rotenone inhibition. We conclude that the 3733G→A transition is a novel cause of LHON and, after those at positions 3460 and 4171, is the third ND1 mutation to be identified in multiple unrelated families. This finding shows that, in addition to ND6, the ND1 subunit gene is also a mutational hot spot for LHON. Ann Neurol 2004;56:631–641

Collaboration


Dive into the Alessandra Lugaresi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marc Girard

Université de Montréal

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vincent Van Pesch

Cliniques Universitaires Saint-Luc

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge